News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Anthony E. Maida III, PhD, MA, MBA

Articles by Anthony E. Maida III, PhD, MA, MBA

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

Latest Updated Articles

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
October 30th 2025

Trending on CancerNetwork

EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process

Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial

FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer

Orca-T Improves Chronic GVHD-Free Survival in Hematologic Cancers

TIP12 Validation of a Multimodal Artificial Intelligence Prognostic Model in Early-Stage HR+/HER2− Breast Cancer